Improvement of survival and prospect of cure in patients with metastatic breast cancer

被引:59
|
作者
Cheng, Yee Chung [3 ]
Ueno, Naoto T. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Dept Breast Med Oncol & Stem Cell Transplantat, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Cellular Therapy, Houston, TX 77030 USA
[3] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA
基金
美国国家卫生研究院;
关键词
Metastatic breast cancer; Chemotherapy; Targeted therapy; Radiation therapy; Surgery; HIGH-DOSE CHEMOTHERAPY; STEM-CELL TRANSPLANTATION; LONG-TERM SURVIVAL; HEPATIC ARTERIAL INFUSION; DISEASE-FREE SURVIVAL; LIVER METASTASES; BRAIN METASTASES; RADIOFREQUENCY ABLATION; SURGICAL-TREATMENT; PROGNOSTIC-FACTORS;
D O I
10.1007/s12282-011-0276-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with metastatic breast cancer have traditionally been considered incurable with conventional treatment. However, 5-10% of those patients survive more than 5 years, and 2-5% survive more than 10 years. Recent studies suggest that the survival of patients with metastatic breast cancer has been slowly improving. In this review, we examine the possible curative approach for a certain group of patients with metastatic breast cancer. We identify that patients most likely to benefit from such an aggressive approach are young and have good performance status, adequate body functional reserve, long disease-free interval before recurrence, oligometastatic disease, and low systemic tumor load. An aggressive multidisciplinary approach including both local treatment of macroscopic disease and systemic treatment of microscopic disease can result in prolonged disease control in certain patients with metastatic breast cancer. Whether patients with prolonged disease control are "cured" remains controversial.
引用
收藏
页码:191 / 199
页数:9
相关论文
共 50 条
  • [21] SURVIVAL OF PATIENTS WITH METASTATIC BREAST-CANCER DIAGNOSED BETWEEN 1955 AND 1980
    DEBONIS, D
    TERZ, JJ
    ELDAR, S
    HILL, LR
    JOURNAL OF SURGICAL ONCOLOGY, 1991, 48 (03) : 158 - 163
  • [22] Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer
    Mary A. Bewick
    Michael S. C. Conlon
    Robert M. Lafrenie
    Breast Cancer Research and Treatment, 2009, 117 : 667 - 669
  • [23] Impact of body mass index on overall survival in patients with metastatic breast cancer
    Saleh, Khalil
    Carton, Matthieu
    Dieras, Veronique
    Heudel, Pierre-Etienne
    Brain, Etienne
    D'Hondt, Veronique
    Mailliez, Audrey
    Patsouris, Anne
    Mouret-Reynier, Marie-Ange
    Goncalves, Anthony
    Ferrero, Jean Marc
    Petit, Thierry
    Emile, George
    Uwer, Lionel
    Debled, Marc
    Dalenc, Florence
    Jouannaud, Christelle
    Ladoire, Sylvain
    Leheurteur, Marianne
    Cottu, Paul
    Veron, Lucie
    Savignoni, Alexia
    Courtinard, Coralie
    Robain, Mathieu
    Delaloge, Suzette
    Deluche, Elise
    BREAST, 2021, 55 : 16 - 24
  • [24] Metastatic breast cancer patients' expectations and priorities for symptom improvement
    Tometich, Danielle B.
    Mosher, Catherine E.
    Hirsh, Adam T.
    Rand, Kevin L.
    Johns, Shelley A.
    Matthias, Marianne S.
    Outcalt, Samantha D.
    Schneider, Bryan P.
    Mina, Lida
    Storniolo, Anna Maria V.
    Newton, Erin V.
    Miller, Kathy D.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (11) : 3781 - 3788
  • [25] No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy
    Bernards, N.
    Creemers, G. J.
    Nieuwenhuijzen, G. A. P.
    Bosscha, K.
    Pruijt, J. F. M.
    Lemmens, V. E. P. P.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3056 - 3060
  • [26] The role of surgery in metastatic breast cancer
    Ruiterkamp, Jetske
    Ernst, Miranda F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S22
  • [27] Role of surgery in metastatic breast cancer
    Medina-Franco, Heriberto
    Lizbeth Suarez-Bobadilla, Yoli
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (01): : 81 - 88
  • [28] The Impact of Locoregional Treatment on Survival in Patients With Metastatic Breast Cancer: A National Cancer Database Analysis
    Kim, Kristine N.
    Qureshi, Muhammad M.
    Huang, Daniel
    Ko, Naomi Y.
    Cassidy, Michael
    Oshry, Lauren
    Hirsch, Ariel E.
    CLINICAL BREAST CANCER, 2020, 20 (02) : E200 - +
  • [29] Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Ushijima, Masaru
    Takahashi, Shunji
    Tokudome, Nahomi
    Sugihara, Tsutomu
    Iwase, Takuji
    Matsuura, Masaaki
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 865 - 871
  • [30] Metastatic breast cancer patients’ expectations and priorities for symptom improvement
    Danielle B. Tometich
    Catherine E. Mosher
    Adam T. Hirsh
    Kevin L. Rand
    Shelley A. Johns
    Marianne S. Matthias
    Samantha D. Outcalt
    Bryan P. Schneider
    Lida Mina
    Anna Maria V. Storniolo
    Erin V. Newton
    Kathy D. Miller
    Supportive Care in Cancer, 2018, 26 : 3781 - 3788